To address this point, we treated in vitro CLL cells for 24 h with either ibrutinib, JAK2/STAT3 inhibitors (i.e., AG490 or Stattic), or both drugs, in the presence or not of BMSC layers. The gene discussed is JAK2; the disease is B-cell chronic lymphocytic leukemia.